Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5597276 | 1.00 | ALDH1A1 (0.34) | ALDH1A1POLBHPGDSMN1; SMN2L3MBTL1 | |
| SCHEMBL691440 | 0.84 | ALDH1A1 (0.46) | ALDH1A1POLBHPGDSMN1; SMN2L3MBTL1 | |
| SCHEMBL691439 | 0.84 | ALDH1A1 (0.46) | ALDH1A1POLBHPGDSMN1; SMN2L3MBTL1 | |
| SCHEMBL5062797 | 0.79 | ALDH1A1 (0.40) | ALDH1A1POLBHPGDSMN1; SMN2L3MBTL1 | |
| SCHEMBL5062800 | 0.79 | ALDH1A1 (0.40) | ALDH1A1POLBHPGDSMN1; SMN2L3MBTL1 | |
| SCHEMBL5608053 | 0.76 | GRM2 (0.30) | — | |
| Nitrous Acid SCHEMBL4243378 | 0.74 | ALDH1A1 (0.36) | ALDH1A1POLBHPGDSMN1; SMN2L3MBTL1 | |
| SCHEMBL4243375 | 0.67 | CTSL (0.31) | — | |
| SCHEMBL5597164 | 0.66 | ROCK1 (0.50) | — | |
| SCHEMBL5065108 | 0.64 | ALDH1A1 (0.54) | ALDH1A1POLBHPGDSMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070161665-A1 | Cancer treatment method | SMITHKLINE BEECHAM CORPORATION | 2007-07-12 | — | — | US | disclosed |
| EP-1682123-A1 | CANCER TREATMENT METHOD | SmithKline Beecham (Cork) Limited (IE) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005046678-A1 | CANCER TREATMENT METHOD | SMITHKLINE BEECHAM (CORK) LIMITED (IE) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161665-A1 | Cancer treatment method | ERBB2, EGFR, PIK3CA | ALDH1A1 2956/4885POLB 896/4885HPGD 2750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.